Mallinckrodt Up On New York's Support For Opioid Settlement
Zacks Investment Research | Mar 11, 2020 09:35PM ET
Shares of Mallinckrodt plc (NYSE:MNK) surged almost 40% on Wednesday amid sell-off in the broader S&P 500 Index, following the support of New York State Attorney General for the company’s previously announced proposed global opioid settlement. Including New York, 48 states and territories are now supporting the proposed settlement.
The motion to remove Mallinckrodt LLC and SpecGx LLC from the New York State trial related to opioid-abuse is currently pending before the Supreme Court of New York. However, the trial has been postponed indefinitely due to the coronavirus scare.
Mallinckrodt’s stock has slumped 86% in the past year compared with the industry ’s decline of 10.7%.
Last month, Mallinckrodt and its specialty generics-focused subsidiaries Mallinckrodt LLC, SpecGx LLC, and certain other affiliates proposed an agreement in principle on the terms of a global settlement that would resolve all opioid-related claims against the company, Specialty Generics, and other subsidiaries.
The agreement in principle has been reached with a court-appointed plaintiff executive committee, representing the interests of thousands of plaintiffs in the opioid multidistrict litigation. Mallinckrodt expects that Specialty Generics, which manufactures certain generic opioid products, among other products, will file voluntary petitions under Chapter 11 of the U.S. Bankruptcy Code in the coming months. The settlement terms include structured payments of $1.3 billion over eight years and warrants for 19.99% of the company's outstanding shares. Additional $300 million will be paid to the plaintiffs upon Specialty Generics’ emergence from bankruptcy.
We note that Mallinckrodt has entered into a number of settlement agreements related to opioid abuse in 2019. A global settlement of the opioid litigation will remove a major overhang on the stock.
Apart from Mallinckrodt, many pharma companies like J&J (NYSE:JNJ) Endo International (NASDAQ:ENDP) and Teva Pharma (NYSE:TEVA) are embroiled in multiple opioid litigations filed by several states, counties and political subdivisions in the United States regarding the abuse of opioid-based drugs. The industry players have been accused of faulty marketing practices, which downplayed addiction risks from these drugs and spurred their consumption instead.
Per the National Institute of Drug Abuse, opioid overdose claimed lives of 47,000 Americans in 2017. Moreover, prescription opioid misuse alone creates a total economic burden of $78.5 billion every year. In the past two decades, 400,000 deaths occurred due to opioid-based drug abuse, per the estimate of Centers for Disease Control and Prevention.
Get The News You Want
Mallinckrodt public limited company Price
Original post
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.